Low Expression of ARHGAP40 in Colorectal Cancer Facilitates Tumor Progression by Activating the RhoA Pathway
ARHGAP40 is downregulated in CRC, and its loss may contribute to tumor progression, possibly through dysregulation of RhoA activity.
We have 2 of 2 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
ARHGAP40 is downregulated in CRC, and its loss may contribute to tumor progression, possibly through dysregulation of RhoA activity.
UBE2A was shown to be a promising prognostic biomarker associated with tumor progression, cell cycle activity and immune-associated characteristics across cancer types and may serve as a potential therapeutic target and a candidate biomarker for evaluating tumor prognosis and the tumor immune microenvironment.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.